EveliQure Biotechnologies

Executive Summary

EveliQure Biotechnologies is a Vienna-based private biotech company developing novel vaccines to prevent diarrhoeal diseases, targeting both travelers and populations in low- and middle-income countries. Founded in 2018, the company leverages innovative platform technologies to address a significant unmet medical need, as diarrhoeal diseases remain a leading cause of morbidity and mortality in endemic regions. EveliQure is currently in Phase 2 clinical development, positioning it to potentially deliver a much-needed intervention that could have both commercial and global health impact. The company's lead vaccine candidate targets enterotoxigenic E. coli (ETEC) and other enteric pathogens, with a focus on oral administration to induce mucosal immunity. Phase 2 data, expected in late 2026, will be a key value inflection point. EveliQure has secured funding from European innovation programs and collaborations with global health organizations, underscoring the public health relevance of its mission. If successful, the vaccine could address a multi-billion-dollar market while improving health equity. Key upcoming catalysts include Phase 2 interim readout, potential regulatory designations, and new strategic partnerships for manufacturing and distribution in endemic regions.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 interim efficacy data readout45% success
• H2 2026Partnership or funding from global health organizations (e.g., Gates Foundation)60% success
• TBDRegulatory designation (e.g., PRIME, Breakthrough Therapy) from EMA or FDA50% success